Cidara Therapeutics, Inc. (CDTX) Earnings History
Annual and quarterly earnings data from 2012 to 2024
Loading earnings history...
CDTX EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
CDTX Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | 100.0% | -13811.9% | -13319.8% |
| 2023 | -57.9% | -116.2% | -98.5% |
| 2022 | 100.0% | -52.0% | -52.1% |
| 2021 | -47.4% | -85.2% | -85.7% |
| 2020 | 100.0% | -595.4% | -597.6% |
Download Data
Export CDTX earnings history in CSV or JSON format
Free sign-in required to download data
Cidara Therapeutics, Inc. (CDTX) Earnings Overview
As of May 6, 2026, Cidara Therapeutics, Inc. (CDTX) reported trailing twelve-month net income of -$185M, reflecting -409.5% year-over-year growth. The company earned $-11.88 per diluted share over the past four quarters, with a net profit margin of -13319.8%.
Looking at the long-term picture, CDTX's historical earnings data spans multiple years. The company achieved its highest annual net income of -$792,000 in fiscal 2012.
Cidara Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including ACAD ($261M net income, 23.6% margin), AGIO (-$423M net income, -764.0% margin), PRAX (-$303M net income), CDTX has room to improve margins relative to the peer group. Compare CDTX vs ACAD →
CDTX Earnings vs Peers
Earnings metrics vs comparable public companies
CDTX Historical Earnings Data (2012–2024)
13 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$170M | -640.6% | -$176M | $-26.75 | -13319.8% | -13811.9% |
| 2023 | -$23M | +31.7% | -$27M | $-5.25 | -98.5% | -116.2% |
| 2022 | -$34M | +20.9% | -$34M | $-9.61 | -52.1% | -52.0% |
| 2021 | -$42M | +41.1% | -$42M | $-16.19 | -85.7% | -85.2% |
| 2020 | -$72M | -75.5% | -$72M | $-36.03 | -597.6% | -595.4% |
| 2019 | -$41M | +30.4% | -$42M | $-26.78 | -196.5% | -199.5% |
| 2018 | -$59M | -5.9% | -$63M | $-45.62 | - | - |
| 2017 | -$56M | -15.7% | -$56M | $-63.69 | - | - |
| 2016 | -$48M | -49.6% | -$48M | $-66.49 | - | - |
| 2015 | -$32M | -170.7% | -$32M | $-46.76 | - | - |
See CDTX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CDTX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CDTX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCDTX — Frequently Asked Questions
Quick answers to the most common questions about buying CDTX stock.
Is CDTX growing earnings?
CDTX EPS fell to $-11.88, with earnings declining -409.5%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-185M.
What are CDTX's profit margins?
Cidara Therapeutics, Inc. net margin is -13319.8%, with operating margin at -13811.9%. Below-average margins reflect competitive or cost pressures.
How consistent are CDTX's earnings?
CDTX earnings data spans 2012-2024. The declining earnings trend is -409.5% YoY. Historical data enables comparison across business cycles.